Anima Biotech: Lighting The Way In Protein Translation
Emerging Company Profile: With a new partner in Eli Lilly, Anima Biotech and its disruptive technology that controls protein translation is starting to make waves as it urges the industry to see the light.
You may also be interested in...
Asia Deal Watch: Takeda Keeps Up Hectic Deals Pace Via Three New Alliances
Takeda pursues RNA-targeting R&D with Evotec and Anima, looks into liver disease with Genevant. Plus deals involving Kyowa Kirin/Twist, Bright Peak/Ajinimoto & Torii/Verrica.
BIO-Europe Spring 2019: Anima Brings Small Molecule Discovery To mRNA Space
Yochi Slonim, co-founder and CEO of Anima Biotech, explains how the company occupies a unique space in mRNA-based drug development.
Start-Up Quarterly Statistics: Q3 Financings Slump Despite Large Gossamer Series B, Big Rubius IPO
Third quarter biopharma start-up financing activity decreased from the record-breaking Q2. A review of biopharma start-up dealmaking and financing activity from July through September 2018, based on data from Strategic Transactions.